

---

**Product Data Sheet**

---

Product Name:  $\beta$ -Amyloid (1-42), human TFA

Cat. No.: GC16243

**Chemical Properties**

Cas. No. 107761-42-2

Formula  $C_{203}H_{311}N_{55}O_{60}S$ 

M.Wt 4514.08

Solubility

Storage

Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure  $\beta$ -Amyloid (1-42), human TFA**Protocol****Cell experiment****[1]:**

Cell lines PC12, cerebral cortex neurons

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

**Product Data Sheet**

---

**Preparation Method**  $\beta$ -Amyloid (1-42), human TFA was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 1 mM and pre-incubated at 37°C for 7 days to promote aggregation and then diluted in medium, then oligomerized  $\beta$ -Amyloid (1-42) (equivalent to 1 mM peptides) were prepared for  $\beta$ -Amyloid (1-42) insult experiments. For PC12 cellular AD model construction, PC12 cells were firstly cultured in 20 ng/ml nerve growth factor (NGF) and 10% FBS for 72 h at 37°C with 95% air and 5% CO<sub>2</sub> to promote PC12 cells differentiation, and then 1  $\mu$ M of oligomerized  $\beta$ -Amyloid (1-42) were added for 24 h to build PC12 cellular AD models. For cellular AD model of cerebral cortex neurons, 1 mM of oligomerized  $\beta$ -Amyloid (1-42) peptides was added in primary cerebral cortex neurons for 24 h to build cellular AD model of cerebral cortex neurons.

**Reaction Conditions** 1  $\mu$ M for 24 h

**Applications** Cell viability was reduced in  $\beta$ -Amyloid (1-42) insult group compared with a control group in NGF stimulated PC 12 cells and primary cerebral cortex neurons from rat embryo cells, indicating successes in the construction of cellular AD models.

**Animal  
experiment [2]:**

**Animal models** Male Wistar rats weighing 210-230 g

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

**Product Data Sheet**

---

Preparation Method	AD model was induced by $\beta$ -Amyloid (1-42) dissolved in normal saline at the concentration of 4 $\mu\text{g}/\mu\text{l}$ . The solution was kept at room temperature for 3 days before administration <sup>75</sup> . $\beta$ -Amyloid (1-42) or saline was injected in a volume of 2 $\mu\text{l}$ over 5 min via a microsyringe pump connected to the 25-gauge stainless steel needle bilaterally into the lateral cerebral ventricles according to stereotaxic coordination.
Dosage form	4 $\mu\text{g}/\mu\text{l}$ , 2 $\mu\text{l}$ , lateral cerebral ventricle injection
Applications	Immunostaining of $\beta$ -Amyloid (1-42) of entorhinal cortex (EC), and dorsal hippocampus (dHPC) sections demonstrated a high level of A $\beta$ plaques in $\beta$ -Amyloid (1-42) animals compared to the saline group.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

### References:

- [1]: Yang H, Wang H, Shang H, et al. Circular RNA circ\_0000950 promotes neuron apoptosis, suppresses neurite outgrowth and elevates inflammatory cytokines levels via directly sponging miR-103 in Alzheimer's disease[J]. Cell Cycle, 2019, 18(18): 2197-2214.
- [2]: Salimi M, Tabasi F, Abdolsamadi M, et al. Disrupted connectivity in the olfactory bulb-entorhinal cortex-dorsal hippocampus circuit is associated with recognition memory deficit in Alzheimer's disease model[J]. Scientific Reports, 2022, 12(1): 1-13.

### Background

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

### Background

$\beta$ -Amyloid (1-42), human TFA is a 42-amino acid peptide. Alzheimer's disease (AD) is characterized phenotypically by memory impairment, neurochemically by accumulation of  $\beta$ -amyloid peptide (such as  $\beta$ -Amyloid (1-42)) and morphologically by an initial loss of nerve terminals in cortical and hippocampal regions [1]. The abnormal production of soluble forms of  $\beta$ -amyloid peptides (A $\beta$ ), such as  $\beta$ -Amyloid (1-42), have been proposed as a major culprit in AD [2].

$\beta$ -Amyloid (1-42) can impair synaptic function, typified by its ability to affect synaptic plasticity [3], and trigger events leading to a loss of viability of synapses [4], and leads to memory impairment [5]. The intracerebroventricular administration of  $\beta$ -Amyloid (1-42) has been proposed as a model of AD [6].

$\beta$ -Amyloid (1-42) (100  $\mu$ g/ml) for 24 h cell viability of SH-SY5Y cells dropped to about 50%,  $\beta$ -Amyloid (1-42)-induced cell apoptosis could be completely prevented by EGb761 at 100  $\mu$ g/ml and to a lesser extent, by quercetin (1.5  $\mu$ g/ml) and ginkgolide B (10  $\mu$ g/ml) [7].

$\beta$ -Amyloid (1-42) (icv. 2 nmol in 4  $\mu$ l) caused a predominant loss of glutamatergic and cholinergic markers [1].  $\beta$ -Amyloid (1-42) was combined with inducers of oxidative stress to induce neuronal cell death, amyloid deposits, gliosis and memory impairment following a 4 week intracerebroventricular infusion. Oxidative stress was induced using the pro-oxidative cation Fe<sup>2+</sup> and the glutathione synthesis inhibitor buthionine sulfoximine (BSO) [8].

### References:

- [1]. Canas P M, Simões A P, Rodrigues R J, et al. Predominant loss of glutamatergic terminal markers in a  $\beta$ -amyloid peptide model of Alzheimer's disease[J]. *Neuropharmacology*, 2014, 76: 51-56.
- [2]. Hardy J, Selkoe D J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics[J]. *science*, 2002, 297(5580): 353-356.
- [3]. Venkitaramani D V, Chin J, Netzer W J, et al.  $\beta$ -amyloid modulation of synaptic transmission and plasticity[J]. *Journal of Neuroscience*, 2007, 27(44): 11832-11837.
- [4]. Mattson M P, Partin J, Begley J G. Amyloid  $\beta$ -peptide induces apoptosis-related events in synapses and dendrites[J]. *Brain research*, 1998, 807(1-2): 167-176.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

- [5].Selkoe D J. Soluble oligomers of the amyloid  $\beta$ -protein: Impair synaptic plasticity and behavior[J]. Synaptic Plasticity and the Mechanism of Alzheimer's Disease, 2008: 89-102.
- [6].Lawlor P A, Young D. A $\beta$  infusion and related models of Alzheimer dementia[M]//Animal models of Dementia. Humana Press, 2011: 347-370.
- [7].Shi C, Zhao L, Zhu B, et al. Protective effects of Ginkgo biloba extract (EGb761) and its constituents quercetin and ginkgolide B against  $\beta$ -amyloid peptide-induced toxicity in SH-SY5Y cells[J]. Chemico-biological interactions, 2009, 181(1): 115-123.
- [8].Lecanu, L., Greeson, J., & Papadopoulos, V. (2006). Beta-amyloid and oxidative stress jointly induce neuronal death, amyloid deposits, gliosis, and memory impairment in the rat brain. Pharmacology, 76(1), 19-33.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA